Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomised placebo-controlled trial

Lancet

Volumn 355, Issue 9217, 2000, Pages 1751-1756

  Boden, William E ^a   Van Gilst, Wiek H ^b   Scheldewaert, Rudy G ^c   Starkey, Ian R ^d   Carlier, Marc F ^e   Julian, Desmond G ^f   Whitehead, Anne ^f   Bertrand, Michel E ^g   Col, Jacques J ^h   Lederballe Pedersen, Ole ⁱ   Lie, Kong I ^f   Santoni, Jean P ^j   Fox, Kim M ^k  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Sythélabo Group   (France)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e Clinique Saint Joseph   (Belgium)

^f Netherhall Gardens ^*

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ VIBORG HOSPITAL   (Denmark)

^j SANOFI   (France)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM ANTAGONIST; DILTIAZEM; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PALPITATION; HEART REINFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; SECONDARY PREVENTION; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; VASODILATATION; VERTIGO;

EID: 0034690671     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02262-5     Document Type: Article

References (38)

1. Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 343:1994;311-322.
2. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 337:1997;1118-1123.
3. Cannon C.P., McCabe C.H., Gibson M.et al. TNK tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 95:1997;351-356.
4. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO) IIB Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
5. Ohman E.M., Kleiman N.S., Talley J.D.et al. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation. Suppl I:1994;56.
6. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
7. Grines C.L., Browne K.F., Marco J.et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 328:1993;673-679.
8. Psaty B.M., Heckbert S.R., Koepsell R.D.et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA. 274:1995;620-625.
9. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
10. Wilcox R.J., Hampton J.R., Banks D.C.et al. Trial of early nifedipine in acute myocardial infarction. the TRENT study BMJ. 293:1986;1204-1248.
11. Early treatment of unstable angina in the coronary care unit: a randomized, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J. 56:1986;400-413.
12. Goldbourt U., Behar S., Reicher-Reiss H., Zion M., Mandelzweig L., Kaplinski E. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israeli Nifedipine Trial 2 Study Arch Intern Med. 153:1993;345-353.
13. Gibson R.S., Boden W.E., Theroux P.et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med. 315:1986;423-429.
14. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
15. Effects of vepramil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol. 66:1990;779-785.
16. Boden W.E., Krone R.J., Kleiger R.E.et al. Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction. Am J Cardiol. 67:1991;335-342.
17. Boden W.E. Electrocardiographic correlates of reperfusion status after thrombolysis: is the "Incomplete" or "Interrupted" infarction a non-Q-wave infarction? Am J Cardiol. 68:1991;520-524.
18. Boden W.E., Scheldewaert R., Walters E.G.et al. Design of a placebo-controlled trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Am J Cardiol. 75:1995;1120-1123.
19. Bianchetti G., Bagheri H., Houin G., Dubruc C., Thenot J.P. Pharmacokinetic and bioavailability of diltiazem sustained-release. influence of food and time of administration Fundam Clin Pharmacol. 9:1995;197-201.
20. Whitehead J. The design and analysis of sequential clinical trials. Revised 2nd edition. 1997;Wiley, Chichester, UK.
21. Brunier H.C., Whitehead J. PEST 3·0 Operating Manual. 1993;University of Reading, UK.
22. SAS PROC LOGISTIC in SAS.STAT User's guide, Version 6, Fourth edition, volume 2. SAS Institute Inc, Cary NC, USA, 1990.
23. Collett D. Modeling survival data in medical research. 1994;Chapman and Hall, London, UK.
24. Yusuf S., Peto R., Lewis J.et al. Beta-Blockade during and after myocardial infarction. an overview of the randomised trials Prog Cardiovasc Dis. 27:1985;335-371.
25. Boden W.E. Cardioprotective effect of long-term diltiazem administration in non-Q wave acute myocardial infarction. Drugs of Today. 30(Suppl A):1994;25-34.
26. Roberts R., Rogers W.J., Mueller H.S.et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) II-B study. Circulation. 83:1991;422-437.
27. Van de Werf F., Janssens L., Brzostek T.et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 22:1993;407-416.
28. Pfeffer M.A., Moyé L.A., Braunwald E.et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA. 226:1991;528-532.
29. Collins R., Julian D. British Heart Foundation Surveys (1987 and 1989) of the United Kingdom policies for acute myocardial infarction. Br Heart J. 66:1991;250-255.
30. Gobel E.J., Hautvast R.W., van Gilst W.H.et al. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. Lancet. 346:1995;1653-1657.
31. Gobel E.J., van Gilst W.H., de Kam P.J.et al. Long-term follow up after early intervention with intravenous diltiazem or intravenous nitroglycerin for unstable angina. Eur Heart J. 19:1998;1208-1213.
32. Pizzetti G., Lu C., Mailhac A.et al. Randomised trial of diltiazem during acute myocardial infarction: effects on myocardial reperfusion. J Am Coll Cardiol. 31( II suppl A):1998;490A.
33. Theroux P., Gregoire J., Chin C., Pelletier G., de Guise P., Juneau M. Intravenous diltiazem in acute myocardial infarction. J Am Coll Cardiol. 32:1998;620-628.
34. Boden W.E., O'Rourke R.A., Crawford M.H.et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 338:1998;1785-1792.
35. Fragmin and Fast Revascularisation during instability in Coronary Artery Disease (FRISC II) Investigators. Long term low-molecular-mass heparin in unstable coronary-artery-disease: FRISC II prospective randomized multicentre study. Lancet. 354:1999;701-707.
36. Buckley M.M., Grany S.M., Goa K.L., McTavish D., Sorkin E.M. Diltiazem. a reappraisal of its pharmacological properties and therapeutic use Drugs. 39:1990;757-806.
37. O'Connor S.E., Grosset A., Janiak P. The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem. Fundam Clin Pharmacol. 13:1999;145-153.
38. Zucker M.L., Budd S.E., Dollar L.E., Chernoff S.B., Altman R. Effects of diltiazem and low-dose aspirin on platelet aggregation and ATP release induced by paired agonists. Thromb Haemost. 70:1993;332-335.